Self-Assessment in Psychopharmacology
A CME Companion to The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Version 2.0
Robert E. Hales, M.D., M.B.A., Narriman C. Shahrokh, Alan F. Schatzberg, M.D., and Charles B. Nemeroff, M.D., Ph.D.
Online at PsychiatryOnline.org
Earn up to 33.5 AMA PRA Category 1 CME Credits
are self-paced, online examinations that allow you to evaluate your mastery of the subject matter as you progress through the companion American Psychiatric Publishing Textbook
The program provides an easy-to-access and individualized opportunity to gain and assess knowledge of psychiatry, ideally to be undertaken by psychiatrists and residents as part of a comprehensive lifelong learning program in psychiatry. It provides a specific educational opportunity for candidates preparing for certification and recertification examinations.
By participating in the Self-Assessment Program, you will have the opportunity to
- Improve knowledge of psychopharmacology
- Improve decision making and patient care
- Test and assess your knowledge and decision-making skills
- Prepare for board certification and recertification
- Practice answering board-like questions
- Earn up to 33.5 AMA PRA Category 1 Credits for each exam
Participants earn continuing medical education (CME) credits for reviewing the companion The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, assessing their retention of the clinical content of the Textbook by taking the self-assessment exam, and further increasing their clinical knowledge by reviewing the rationale for the correct answers. The Answer Guide references relevant text, tables, and figures (including the page number) in the Textbook to allow quick access to needed information. Each answer is accompanied by a discussion that addresses not only the correct response but also explains why other responses are not correct.
The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Psychiatric Association designates this educational activity for a maximum of 33.5 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This Self-Assessment does NOT meet ABPN criteria for Self-Assessment (Part 2 of the Maintenance of Certification).
Program release date: May 1, 2009
Program review date: May 31, 2012
Program end date: May 31, 2015
Preface. Questions. Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders. Basic principles of molecular biology and genomics. Genetics and genomics. Chemical neuroanatomy of the primate brain. Electrophysiology. Animal models. Psychoneuroendocrinology. Principles of pharmacokinetics and pharmacodynamics. Brain�immune system interactions: relevance to the pathophysiology and treatment of neuropsychiatric disorders. Brain imaging in psychopharmacology. Statistics, placebo response, and clinical trial design in psychopharmacology. Tricyclic and tetracyclic drugs. Fluoxetine. Sertraline. Paroxetine. Fluvoxamine. Citalopram and s-citalopram. Monoamine oxidase inhibitors. Trazodone and nefazodone. Bupropion. Mirtazapine. Venlafaxine and desvenlafaxine. Duloxetine and milnacipran. Benzodiazepines. Buspirone and gepirone. Putative new-generation antidepressants. Classic antipsychotic medications. Clozapine. Olanzapine. Quetiapine. Aripiprazole. Ziprasidone. Drugs to treat extrapyramidal side effects. Lithium. Valproate. Carbamazepine and oxcarbazepine. Gabapentin and pregabablin. Lamotrigine. Topiramate. Cognitive enhancers. Sedative-hypnotics. Psychostimulants and wakefulness-promoting agents. Electroconvulsive therapy. Neurobiology of mood disorders. Neurobiology of schizophrenia. Neurobiology of anxiety disorders. Neurobiology of Alzheimer’s disease. Neurobiology of substance abuse and addiction. Neurobiology of eating disorders. Neurobiology of personality disorders. Neurobiology of childhood disorders. Treatment of depression. Treatment of bipolar disorder. Treatment of schizophrenia. Treatment of anxiety disorders. Treatment of agitation and aggression in the elderly. Treatment of substance-related disorders. Treatment of eating disorders. Treatment of insomnia. Treatment of personality disorders. Treatment of psychiatric emergencies. Treatment of childhood and adolescent disorders. Psychopharmacology during pregnancy and lactation. Treatment during late life. Treatment of chronic pain syndromes. Ethical considerations psychopharmacological treatment and research. Answers.
Robert E. Hales, M.D., M.B.A.,
is the Joe P. Tupin Professor and Chair of the Department of Psychiatry at the University of California, Davis School of Medicine. He is also the Editor-in-Chief of the American Psychiatric Publishing, Inc., and Medical Director of the Sacramento County Mental Health Service in Sacramento, California.
Narriman C. Shahrokh is Chief Administrative Officer in the Department of Psychiatry and Behavioral Sciences at the University of California, Davis, School of Medicine in Sacramento, California.
Alan F. Schatzberg, M.D., is Kenneth T. Norris Jr. Professor and Chair of the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine in Stanford, California.
Charles B. Nemeroff, M.D., Ph.D., is Reunette W. Harris Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine in Atlanta, Georgia.